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Abstract- One of the most frequent complications of diabetes is diabetic peripheral neuropathy. 
Hyperglycemia would result in the advancement of this condition over a period of time. The most effective 
way in preventing diabetic neuropathy is regular control of glucose. In this study; we evaluated the effects of 
lithium onstreptozocin (STZ)-induced diabetic neuropathy in rats. Diabetic neuropathy was created 7 weeks 
after administration of STZ (45 mg/kg). Lithium was added to drinking water (450 mg/l) for 7 weeks and its 
plasma level after this period of time was 0.17±0.02 mmol/l. Levels of adenosine triphosphate (ATP) in 
dorsal root ganglion (DRG) neurons, oxidative stress parameters, open-field activity test and morphological 
analysis were assessed in this investigation. Currentresults showed significant elevation of oxidative stress 
biomarkers, reduction of ATP, abnormal morphology of DRG neurons and decrease of total distance moved 
in rats with STZ-induced diabetic neuropathy. The alterations in mentioned parameters were considerably 
restored by lithium treatment. These findings provide evidence for protective effects of lithium on STZ-
induced diabetic neuropathy. 
© 2018Tehran University of Medical Sciences. All rights reserved.  
Acta Med Iran 2018;56(3):151-160. 
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Introduction 
 
Diabetes mellitus is a severe metabolic disorder that 
is increasing due to obesity population growth, aging, 
urbanization, and also socio-economic problems in 
recent years. Uncontrolled chronic hyperglycemia in 
diabetic patients leads to several complications 
including retinopathy, autonomic dysfunctions,and 
nephropathy. Over one-third of diabetics are suffering 
from diabetic neuropathy (1). Hyperglycemia and 
microvascular complications of diabetes stimulate the 
development of diabetic neuropathy (2). 
Diabetic neuropathy is a debilitating disorder that is 
known by widespread damage to peripheral nerves. 
This disease is a progressive disorder that causes 
structural and functional changes in the peripheral and 
central nervous system. According to the complex 
etiology of diabetic neuropathy, various factors, 
including oxidative stress, hypoxia/ischemia of nerves, 
alterations in the protein kinase C pathway, decrease of 
nerve growth factor or even loss of advanced glycation 
end product (AGE) formation are involved in diabetic 
neuropathy disease (3-7). Although the cure for 
diabetic neuropathy is not well known, studies show 
that reduction of oxidative stress is effective in 
controlling of neuropathy. Therefore, the current study 
examined the effect of lithium as a free radicals’ 
scavenger in Streptozotocin (STZ)-induced diabetic 
model in rats. 
Lithium as a light alkali metal is not metabolized in 
the body and also cannot bind to the proteins (8). Some 
investigations show neuroprotective effects of lithium 
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through various mechanisms like reducing expression of 
P53 and Bax as pro-apoptotic markers or enhancing the 
expression of Bcl2 as an anti-apoptotic factor, Ca²⁺ flux 
inhibition via NMDA receptors and inhibition of 
Glycogen Synthase Kinase 3beta (GSK3β) as a 
therapeutic target in central nervous system, cancer, and 
diabetes (9-11). Numerous factors containing glutamate 
excitotoxicity can induce activation of GSK-3 which is 
associated with apoptotic cell death (12). Direct and 
indirect inhibition of GSK-3 by lithium lead to increase 
expression of neuroprotective and neurotrophic proteins 
such as Heats Shock protein 70 (HSP70), Brain-derived 
neurotrophic factor and Bcl-2 (13). Deactivation of 
GSK-3 by lithium also stimulates cell survival 
transcription factors comprising cyclic adenosine 
monophosphate response element-binding protein 
(CREB), b-catenin, and activator protein-1 (13).  
Initial attempts to treat diabetic neuropathy depend 
on glycemic control. However the role of lithium as a 
key player in ATP consumption, DRG histological 
alterations and oxidative stress was not studied 
completely in this disorder. In thepresent study, we 
evaluated the effects of lithium on STZ-induced diabetic 
neuropathy by assessment of lithium plasma level, 
ADP/ATP ratio, histological analysis of DRG neurons, 
and oxidative stress biomarkers. 
 
Materials and Methods 
 
Animals 
Male Wistar rats with age 2-2.5 months and the 
weight of 200-250g were applied in this study and 
acquired from Tehran University of Medical Sciences; 
Faculty of Pharmacy. The rats were maintained in 
stainless cages and provided with free access to food and 
water. They were housed under adjusted lighting cycle 
(12/12hr light/dark cycle). All animal experimental 
procedures were carried out in accordance with Tehran 
University of Medical Sciences ethical guidelines for the 
use and care of laboratory animals. 
 
Experiments 
The animals were randomly divided into four groups 
containing (1) the control group that received 
intraperitoneal (i.p) injection of saline, (2) STZ group 
which received a single i.p. injection of STZ (45 mg/kg), 
(3) lithium-treated group which received lithium (450 
mg/L, orally) in their drinking water for 7 weeks and (4) 
STZ/lithium group which treated with STZ (45 mg/kg, 
i.p.) and lithium chloride (450 mg/L, 7 weeks) via 
drinking water. Administration of lithium was 
simultaneous with STZ injection. 
 
Induction of diabetic neuropathy 
For induction of diabetes, 45 mg/kg of STZ 
dissolved in normal saline and administered i.p. to the 
rats with overnight fasting. One week after STZ 
injection, animals’ blood glucose was measured. 
Animals with blood glucose of over 250 mg/dl were 
considered as diabetic. After two months, diabetic 
neuropathy occurred (14). 
 
Determination of blood glucose level and body weight 
Blood glucose levels and body weight of animals 
were determined respectively by using glucometer 
(Accu-chek-active) and special balance. We determined 
the blood glucose 72hrs and one week after injection of 
STZ to ensure the development of diabetes. 
Furthermore, we measured blood glucose finally, after 
twomonths, before surgery in animals. 
 
Sample preparation 
A mixture of xylazine (20 mg/kg) and ketamine (80 
mg/kg) was administered intraperitoneally to anesthetize 
animals. About 5 ml blood was taken from the heart into 
the tube which contained heparin as an anticoagulant 
agent. Heart blood samples’ were centrifuged at 4°c for 
10 minutes at 1200rpm. Then plasma was kept at -80°c 
for evaluation of stress oxidative parameters. 
For the purpose of tissue separation, the paraspinal 
tissue and spinal cord (C2 to L2) were removed. After 
laminectomy, the spinal ganglia were determined,and 
the sixth cervical DRG neurons on each side were 
detached. The spinal ganglia could be detected after 
removing cervical spine lamina. One or two separated 
DRG neurons were stabilized in formalin (10%),and the 
remaining DRG neurons were stored in liquid nitrogen 
for determining the ADP/ ATP ratio. 
 
Measurement of plasma lithium concentration 
The heart blood was collected in heparinized tubes 
just 7 weeks after induction of diabetes. The samples 
were centrifuged at 1200rpm,and plasma lithium level 
was determined by using a Shimadzu AA-670 Atomic 
absorption spectrophotometer. 
 
Measurement of adenosine diphosphate (ADP) and 
ATP 
All steps were carried out on the ice. The DRG 
neurons were taken from liquid nitrogen and sonicated 
in 250µl of ice-cold trichloroacetic acid (TCA, 6%).  
After centrifuging the extract for10 min at 12000rpm in 
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4°c, KOH (4M) was used to neutralize the supernatant 
and have the final pH of 6.5. Subsequently, it was 
filtered via 0.45µm Millipore mesh. ADP and ATP 
levels were measured in theneutralized extract by using 
Ion-Pair High-Performance Liquid Chromatography (IP-
HPLC) (14). 
 
Measurement of lipid peroxidation 
The precipitate produced from mixing of plasma 
samples and TCA (20%) was dispersed in H2SO4 (0.05 
M),andthiobarbituric acid (TBA) (0.2% in 2 M sodium 
sulfate) and consequently was added to the mixture. The 
samples were incubated for 30 minutes in a boiling 
water bath. The Lipid peroxide (LPO) adducts were 
elicited by addition of n-butanol,and the absorbance was 
measured at 532nm (15). 
 
Measurement of plasma total thiol groups  
The total amount of sulfhydryl in plasma was 
assessed as defined formerly. In the test tube, 0.2 ml of 
plasma was mixed with 0.6 ml of Tris-EDTA buffer 
(Tris base 0.25 M, EDTA 20mM, PH 8.2) and then 40 
ml of DTNB (10mM) in methanol was added to the 
mixture. In order to reach the ultimate volume of 4.0 ml, 
3.16ml of methanol was added. Afterwards, it was 
centrifuged at ambient temperature for 10 minutes at 
3000rpm. The absorbance was assayed at 412nm (16). 
 
Measurement of total antioxidant capacity 
Antioxidant capacity of plasma was assessed by the 
ferric reducing ability of plasma (FRAP) test. By 
reducing ferric to ferrous, a blue colored complex of 
ferrous and tripyridyltriazine (TPTZ) with 
theabsorbance of 593nm was formed (14). 
 
Measurement of reactive oxygen species (ROS) 
In order to assay the activity of ROS, fluorescence 
DCHF was used as a probe with some modifications. 
The assay buffer includedMgCl2(5 mM), KCl (130 
mM), NaH2PO4(20 mM), FeCl3(0.1 mM), NADPH(0.1 
mM), ADP (1.7 mM), Tris-HCl (20 mM) and glucose 
(30 mM ) (PH=7.4, whole volume of 200 µL). In this 
test, theoxidation rate of DCFH to dichlorofluorescein 
(DCF), marker of oxidant generation, was determined at 
the excitation wavelength of 488 nm and emission 
wavelength of 525 nm, by means of ELISA F-2000 
fluorescence spectrometer every 6 min for during 
thetime of 60 min (17).   
 
Evaluation of open-field activity 
Open-field activity test was performed to evaluate 
the effect of diabetic neuropathy on theexplorative 
behavior of rats. The rats were located in the test area 
and allowed to move freely for 15 minutes while all of 
their movements were recorded by a camera. The data 
were analyzed by Ethovision software for measurement 
of two parameters: distance moved and velocity (18). 
 
Histological preparation and morphometric studies 
Generally, DRG neurons were classified as a (large 
cells),and B type (small cells) cells by different 
definitions: cytoplasm of A-cells have a granular 
background with central nucleus, and also thelightly 
stained area around the cytoplasm of several cells can be 
seen in this type of cells. In B-cells, the homogeneity of 
cytoplasm and intensity of staining is more than A-cells. 
Central staining of cytoplasm in some B-cells is lighter 
than the outer parts. 
Here, the tissues were embedded in paraffin after 
dehydration of DRG neurons in graded ethanol and 
clearing in xylol. Then they were sectioned in 40µm size 
by using a microtome. Haematoxylin and eosin were 
used to stain DRG neurons. The morphometric 
evaluation was performed by using HE-stained samples. 
Olympus microscope (LX71, Japan) was used to 
count the number of A and B cells in all groups. 
Stereological studies were performed by image 
evaluation program (Optika, Italy) (18). 
 
Chemicals 
Streptozocin (STZ) was provided from Pharmacia 
and Upjohn Inc. (Kalamazoo, New Jersey, USA). 
Lithium, xylazine, ketamine, Adenosine diphosphate 
(ADP) sodium salt, KH2PO4 (analytical grade), ATP 
disodium salt, methanol (high performance liquid 
chromatography [HPLC]-grade, 5,5΄-dithiobis-2-nitro 
benzoic acid (DTNB), 2-thiobarbituric acid (TBA), 
Tetrabutylammonium hydroxide (TBAHS), n-butanol, 
potassium hydroxide, trichloroacetic acid (TCA), diethyl 
ether, 2,4,6-tripyridyl-s-triazine (TPTZ), Tris-HCl 
buffer, 1,1,3,3-tetraethoxypropane (MDA), MgCl2, 
Haematoxylin-eosin, formalin, xylol, alcohol, 
erythrosine, EDTA, KCL, FeCl3 and NaH2PO4 were 
purchased from Merck (Frankfurt Germany). A 
SUPELCOSIL™ LC-18-T HPLC column was from 
SUPELCO (Antrim, UK), Nicotinamide adenine 
dinucleotide phosphate (NADPH), ADP, 
Dichlorodihydrofluorescein (DCFH) and bovine serum 
albumin (BSA) were supplied from Sigma–Aldrich (St. 
Louis, MO, USA). 
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Statistical analysis 
The results are presented as mean±S.E.M. Statistical 
significance was determined by one-way analysis of 
variance (ANOVA) with post hoc test of Newman-
Keuls. Differences with P of less than 0.05 were 
considered statistically significant. Graph Pad Prism 5 
was used to analyze all obtained data from 
theexperiment. 
 
Results 
 
Assessment of body weight, blood glucose and 
plasma lithium levels in different treated animals 
The body weight of animals was measured after 7 
weeks. The results illustrated noticeable differences 
between different groups in this parameter (F=19.21, 
P<0.0001). Body weight of STZ group significantly 
reduced after 7 weeks in comparison with control and 
lithium-treated animals (P<0.001) (Figure 1). A 
significant increase in body weight in STZ/lithium 
combination group was observed as compared with STZ 
rats (P<0.001) (Figure 1). As shown in figure 1, there 
was no significant difference in body weight 
betweenthecontrol group and lithium-treated animals. 
We evaluated the blood glucose level 7 weeks after 
induction of diabetes by STZ. The results indicated 
significant differences between different groups in blood 
glucose concentration (F=51.09, P<0.0001). Blood 
glucose level in control and lithium group had an 
average of less than 110mg/dl .On the other hand blood 
glucose concentration in STZ and STZ/lithium group 
had an average of more than 250mg/dl.  
The results related to plasma lithium level 7 weeks 
after lithium administration (450 mg/l) demonstrated 
notable differences between different groups (F=65.01, 
P<0.0001). The plasma levels of lithium in lithium and 
STZ/lithium-treated animals were 0.19±0.01 and 
0.17±0.02 mmol/l respectively. In addition, the plasma 
concentrations of lithium in control and diabetic rats 
were 0.007±0.001 and 0.001±0.001 mmol/l. A 
significant difference in lithium concentration was 
observed between control and STZ with either lithium or 
STZ/lithium-treated animals (P<0.0001) (Table 1). 
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Figure 1. Effect of lithium administration on body weight 
Significant reduction in body weight of STZ-induced diabetic neuropathy rats was seen in comparison with control animals (***P<0.001) and lithium 
group (###P<0.001). Body weight was significantly increased in STZ/lithium group comparing to STZ treated rats (###P<0.001). Data are represented as 
mean±S.E.M. of seven animals in each group. * and # show statistical difference between control and STZ treated animals respectively. 
 
Table 1. Blood glucose and lithium plasma level in each group. A significant difference in lithium concentration 
was observed between control and STZ with either lithium or STZ/lithium-treated animals (P<0.0001).Data are 
represented as mean±S.E.M. Each group contains 7 animals 
Treatment Control STZ STZ/lithium Lithium 
Lithium plasma level (mmol/l) 0.007+0.001 0.001+0.001 0.17+0.02 0.19+0.01 
Blood glucose (mg/dl) 98.258 434.667 353.33 100.429 
 
 
Effects of lithium on STZ-induced motor dysfunction 
in neuropathic animals  
In order to assess the motor function, we evaluated 
distance moved and velocity in the open field test 7 
weeks after diabetes induction. The results indicated 
significant differences between different groups in the 
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distance moved (F=4.74, P=0.007). There was a 
significant reduction in distance moved in STZ group 
compared to the control (P<0.01) and lithium-treated 
animals (P<0.05). Treatment with lithium for 7 weeks 
significantly increased distance moved in STZ/lithium 
group compared with STZ group (P<0.05) (Figure 2). 
Additionally, the results demonstrated remarkable 
differences between different groups in velocity 
(F=4.10, P=0.01). Velocity in STZ rats was also 
decreased considerably in comparison with the control 
and lithium groups (P<0.05). A significant improvement 
of velocity was seen similarly in STZ/lithium-treated 
animals compared to STZ group (P<0.05) (Figure 3). As 
represented in figure 2 and figure 3, there was no 
statistical difference between control and lithium-treated 
rats in the distance moved and velocity. 
 
 
Figure 2. Effect of lithium administration on thedistance moved 
The stz-induced diabetic group indicated considerable decrease in distance moved compared to the control (**P<0.01) and lithium group 
(#P<0.05). Lithium treatment in neuropathic group considerably increased the distance moved comparing to the STZ treated animals (#P<0.05). No 
remarkable difference was seen between control animals and lithium group. Data are represented as mean±S.E.M. of seven animals in each group. * 
and # show statistical difference between control and STZ treated animals, respectively. 
 
 
Figure 3. Effect of lithium administration on velocity 
STZ treated animals showed significant decrease in velocity parameter as compared to control (*P<0.05) and lithium (#P<0.05) groups. The 
velocity was significantly increased in STZ/lithium animals comparing to STZ treated group (#P<0.05). No significant difference was seen between 
thecontrol group and lithium-treated rats. Data are represented as mean ± S.E.M. of seven animals in each group,* and # show significant difference 
with control and STZ treated animals, respectively 
 
Assessment of oxidative stress biomarkers in control, 
STZ, lithium,and STZ/lithium-treated animals 
The results showed notable differences between 
different groups in oxidative stress parameters (Thiol: 
F=43, P<0.0001, FRAP: F=3.88, P=0.03, LPO: 
F=13.16, P<0.0001, ROS: F=9.45, 
P=0.01).Intraperitoneal injection of STZ led to a 
remarkable decline of total antioxidant capacity (FRAP) 
(P<0.05) and thiol content (P<0.001) in plasma of STZ 
animals compared to the control group (Table 2). 
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Similarly a significant reduction of total antioxidant 
capacity (FRAP) (P<0.05) and thiol level (P<0.001) was 
also observed in STZ group compare to lithium-treated 
animals. The total thiol amount in STZ/lithium-treated 
animals was elevated remarkably as compared with STZ 
rats (P<0.001). Lipid peroxide (LPO) and reactive 
oxygen species (ROS) levels in plasma of STZ rats were 
significantly increased after 7 weeks of STZ injection in 
comparison with either control (P<0.001) or lithium 
(P<0.001) groups. There was a notable decrease in both 
LPO and ROS plasma levels in STZ/lithium treatment 
group compared to the STZ animals (P<0.001). Data 
showed no considerable differences in oxidative stress 
parameters between thecontrol group and lithium-treated 
rats (Table 2). 
 
Table 2. Effects of lithium administration on different oxidative stress parameters 
Treatment Thiol (mmol/lit) FRAP (mM) LPO (µmol/ml) ROS(u/mg protein) 
Control 228.1+ 5.72 88.9+4.50 303.3+17.44 2.87+0.13 
STZ 121.3+4.95a 61.35+3.27d 407.6+9.88a 5.19+0.69a 
STZ/lithium 188.4+ 5.13b,c 75.23+1.26 318.1+13.16b 2.10+ 0.57b 
Lithium 209.4+ 8.27b 80.17+ 3.98e 297.74+13.55b 2.21+ 0.12b 
There was a significant change in plasma level of different markers in the diabetic neuropathy rats and the control group. Remarkable 
improving effects have been seen in STZ/lithium-treated animals comparing to the STZ treated group. Data are represented as mean ± 
S.E.M. Each group contained 7 animals. (aP<0.001 STZ,cP<0. and dP<0.05  the letters a, b and c are showing the comparison between 
the control group and other groups,bP<0.001 letter b shows the comparison between lithium and STZ/Li group with STZ group, 
eP<0.05 the letter e is showing the comparison between Li group and STZ group) 
 
 
Analysis of ADP/ATP ratio in neurons of dorsal root 
ganglion 
The result obtained from assessment of ADP/ATP 
ration in DRG revealed significant differences between 
different group (F=149.8, P<0.0001). Diabetes-induced 
by STZ resulted in a significant increase in the 
ADP/ATP ratio in dorsal root ganglion neurons of STZ 
rats in comparison with the control and lithium-treated 
animals (P<0.001). Lithium by increasing ATP level 
caused a significant attenuation of ADP/ATP ratio in 
STZ/lithium-treated rats compared to the animals which 
received STZ alone (P<0.001). No significant changes 
were seen between lithium-treated animals and control 
group (Figure 4). 
 
 
Figure 4. Effect of lithium administration on ADP/ATP ratio in dorsal root ganglion 
There was a significant increase in ADP/ATP ratio in STZ-treated rats in comparison with the control (***P<0.001) and lithium group 
(###P<0.001). ADP/ATP ratio had a significant decrement in STZ/lithium-treated animals comparing to STZ treated rats (###P<0.001). A significant 
difference in ADP/ATP ratio was also seen between STZ/lithium-treated animals and the control group (**P<0.01). No considerable difference was 
observed between thecontrol group and lithium-treated rats. Data are represented as mean±S.E.M of seven animals in each group,* and # show 
significant difference with control and STZ treated animals, respectively. 
 
Histological effects of lithium on the number of large 
(A) and small (B) cells 
The result of Histological studies on A and B cells 
illustrated considerable differences between different 
groups (A cells: F=16.45, P<0.0001, B cells: F=5.86, 
P=0.006). There was a significant decline in the number 
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of large neurons (A cells) in STZ animals compared to 
control group (P<0.001) (Figure 5A). A considerable 
decrease was also seen in the number of large neurons in 
STZ/lithium-treated animal compare to control group 
(P<0.05) (Figure 5A). The number of large cells in 
STZ/lithium-treated group was significantly elevated as 
compared to STZ animals (P<0.05) (Figure 5A). The 
number of small cells (B cells) was significantly 
increased in STZ group in comparison with control rats 
(P<0.01). A remarkable decrease was also seen in the 
number of small cells (B cells) in STZ/lithium-treated 
animals compared with STZ group (P<0.05) (figure 5B). 
No significant difference was observed between lithium 
exposed animals and control group in the number of 
large and small cells (data not shown). 
 
 
Figure 5. Effect of lithium administration on the number of large (A) and small (B) cells 
A significant reduction in the number of A cells was observed between STZ treated animals and control group (A, ***P<0.001). Administration 
of lithium increased the number of A cells in STZ/lithium-treated rats compared to STZ group (A, #P<0.05). The number of B cells was considerably 
increased in STZ treated group comparing to the control rats (B, **P<0.01). The considerable decrease was observed in the number of B cells in 
STZ/lithium animals compared to STZ treated rats (B, #P<0.05). No significant difference was observed between control group and STZ/lithium 
group. Data are represented as mean±S.E.M of seven animals in each group. * and # show significant difference between control and STZ treated 
animals respectively. 
 
Discussion 
 
In the present study, we aimed to investigate the 
effects of lithium on STZ-induced diabetic neuropathy. 
Administration of lithium mainly improved oxidative 
stress parameters, motor function, and ADP/ATP ratio in 
a rat model of diabetic neuropathy.  
In vitro and in vivo studies have revealed that there 
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are different biochemical pathways which are 
presumably involved in the progression of diabetic 
consequences, including polyol and hexosamine 
pathways, aberrant activity of protein kinase C and 
production of advanced glycation end products. 
Although each pathway may be harmful alone, they can 
result in instability state of mitochondria together, which 
leads to overproduction of ROS (2). Diabetic neuropathy 
induced by STZ was characterized by neuronal blood 
flow deficiency and also complications in nerve 
conductivity in diabetic rats (19). Deoxyglucose and 
nitrosourea as two segments of STZ are responsible for 
improving the ability of STZ cell permeability and 
toxicity of pancreatic β cells respectively that can cause 
an increase in blood glucose (20). 
Vascular impairment followed by the high level of 
oxidative stress markers in diabetic rats results in 
endoneurial hypoxia and thereby reducing nerve 
conduction velocity and neuronal dysfunctions (20). 
High blood glucose concentration activates polyol 
pathway which reduces Na/K ATPase, myoinositol and 
NADPH activities. Reduction in NADPH activity 
prevents energy metabolism and subsequently attenuates 
the nerve conduction ability (20). Thus, the consequence 
of approximately all pathophysiological pathways 
involved in diabetic neuropathy is oxidative stress as the 
main cause of this condition (21).  
Lithium, a monovalent cation, has been used to treat 
bipolar disorders for more than 60 years (22). It seems 
that plasma level of lithium has an important role in its 
biological effects. In our investigation, plasma lithium 
level of 0.17±0.02 mmol/l revealed anti-oxidant and 
protective effects on STZ-induced diabetic neuropathy. 
Chronic lithium therapy can prevent neuronal cell death 
and retardation of neurogenesis by enhancing protective 
markers and decreasing the pro-apoptotic biomarkers 
(11,23). Acquired results from our previous study in 
improving motor function and enhancement of nerve 
conduction velocity by administration of lithium in 
paclitaxel-induced neuropathy (24) show that one of the 
probable mechanisms of lithium is theprotection of 
neurons against hypoxia. In our investigation, no 
significant differences were seen in biochemical and 
behavioral parameters between lithium-treated animals 
and control group. 
Diabetic neuropathy’s in vitro model determines that 
high blood glucose suppresses regular mitochondrial 
function in DRG neurons (25). Augmentation of 
metabolic flux due to the high blood glucose motivates 
theexcess production of ROS (26). ROS are generated in 
electron transport chain of mitochondria and detoxified 
by glutathione, catalase, and superoxide dismutase as 
free radical scavengers. Overproduction of reactive 
oxygen species saturates capacity of the cell antioxidants 
which can lead to injuries of protein, lipid, and DNA 
(2,25). Recent study on oxidative stress and apoptosis 
induced by high glucose in PC12 cells indicated that 
lithium could decrease oxidative stress factors (27). 
Through long-term lithium therapy, increasing in 
glutathione concentration and preventing cell death 
mediated by H2O2 as reactive oxygen metabolite, were 
seen in primary cultured rat cerebral cortical cells (22). 
Various biochemical alterations have been assumed for 
neurotrophic properties of lithium against apoptosis and 
oxidative stress, including raise of the anti-apoptotic 
proteins, reduction of the pro-apoptotic biomarkers (22) 
and blocking of cytochrome C leakage (28). Also, it has 
been reported that high glucose-induced apoptosis was 
reduced by lithium administration in PC12 cells (27). 
Therefore, these consequences propose that the 
enhancement of anti-apoptotic factors caused by lithium 
can be partly considered as a probable mechanism of 
lithium in attenuating of diabetic neuropathy problems. 
Moreover, according to our finding that lithium reversed 
STZ-induced oxidative stress, thus it is possible that 
lithium by affecting ROS and other related pathways 
protect neurons against neuropathic situations.   
In addition, analysis of ADP/ATP ratio of DRG 
indicated that this ratio increased in diabetic animals 
comparing to the control group. We showed a decline in 
this proportion after treatment with lithium. Apoptosis 
of neurons is developed by interruption of electron 
transport chain of mitochondria and ATP depletion. 
ATP depletion is caused by NADH agglomeration and 
also mitochondrial creatine phosphate pump failure in 
converting ADP to ATP (26). Even a slight decrease in 
the function of mitochondria and subsequent discharge 
of ATP may have noticeable effects on theperipheral 
nervous system (1). According to the results obtained in 
this study, it can be expected that lithium by reducing 
oxidative stress can improve the performance of 
mitochondria and thereby prevent energy depletion. The 
effect of lithium on insulin/glucose modulation is also 
not negligible (31). It is possible that lithium-induced 
oxidative stress inhibition and preventing of ATP 
depletion affect insulin/glucose functional attitude which 
needs to be clarified by details in future studies.  
Elevation of oxidative stress and mitochondrial 
dysfunction are involved in the pathogenesis of 
neurodegenerative diseases such as Alzheimer disease 
(AD), Parkinson, diabetic neuropathy (29) and 
Amyotrophic lateral sclerosis (ALS) (30). 
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Neuroprotection mechanisms of lithium that proposed 
by recent evidence are improvement of mitochondrial 
dysfunction, reduction of oxidative stress, and protection 
against DNA damage caused by oxidative stress (30).   
Development of oxidative stress coupled with 
thedischarge of ATP within apoptotic process can 
induce Na/K pump dysfunction (32). Reduction of Na/K 
ATPase activity may be the result of ATP depletion and 
seems to have a significant role in the pathophysiology 
of diabetic neuropathy (1). Several studies have shown 
that decreasing of Na/K ATPase activity in neuronal 
tissues can induce the progress of diabetic neuropathy 
(33). A number of studies have also confirmed that 
lithium could enhance Na/K ATPase activity of 
erythrocytes in manic-depressive patients (34). 
Furthermore, thesubstantial relevance between enzyme 
activity and lithium level has been detected (34). 
Research on animal models of ALS treated with lithium 
has shown considerable improvement in motor function. 
The principal assumption mechanism of lithium for such 
improvement was motivating autophagy (30). Since our 
data also represent the improvement of velocity in 
diabetic neuropathy rats, further studies need to be 
performedto determine the involved mechanism. 
Diabetic rat neurons have shown different 
characteristics including smaller cells, more vacuoles with 
larger sizes and stronger basophilic staining (18). Slowing 
of nerve conduction velocity is because of losing large 
neurons (35). Although thetotal count of large and small 
cells are approximately equal in diabetic neuropathy and 
control group, large to small neurons ratio decrease under 
diabetic neuropathy condition (18). Regarding our results 
which show considerable increase of large cells and also 
significant reduction of small cells in Li/STZ treated 
animals and STZ group, it is convincible to consider 
lithium as a protective cause against STZ-induced 
histological alterations in neuropathic rats. Moreover, in 
vitro cell/cell line studies of pancreatic cells and dorsal 
root ganglion would contribute to understanding the 
mechanisms underlying an eventual protective effect of 
lithium against diabetic neuropathy which should have 
done in near future studies.  
As a conclusion, present findings demonstrate 
beneficial effect of the treatment with lithium in diabetic 
neuropathy rats by enhancing motor function, increasing 
ATP, improving stress oxidative parameters, and 
refining of histological alteration of DRG. However, 
more investigations are needed to clarify the other 
interfering mechanisms and evaluate whether lithium 
could have place in the preventing of diabetic 
neuropathy in clinic. 
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